Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

OTHER 3NIH 1FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 24Neoplasms 22Carcinoma, Merkel Cell 20Neoplasm Metastasis 18Carcinoma, Renal Cell 17Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Gemcitabine 13pembrolizumab 9Specimen Handling 9enfortumab vedotin 8Cisplatin 8Magnetic Resonance Spectroscopy 7avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3eribulin 2cabozantinib 2Standard of Care 2Ramucirumab 2Radiotherapy 2Platinum 2Nephroureterectomy 2Ipilimumab 2Doxorubicin 2Docetaxel 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Ureteral Neoplasms × avelumab × Clear all
NCT05092958 2026-05-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
654 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04004442 2026-03-13

COAXIN

University of Oklahoma

Phase 1 Active not recruiting
19 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Mayo Clinic

Phase 2 Completed
2 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡